Skip to main content

01.12.2015 | Research article | Ausgabe 1/2015 Open Access

BMC Urology 1/2015

Sacral neuromodulation for the treatment of neurogenic lower urinary tract dysfunction caused by multiple sclerosis: a single-centre prospective series

BMC Urology > Ausgabe 1/2015
Daniel S. Engeler, Daniel Meyer, Dominik Abt, Stefanie Müller, Hans-Peter Schmid
Wichtige Hinweise

Competing interests

DSE has received speaker honoraria from Medtronic Inc. and has participated in a trial by this company. All other authors declare that they have no competing interests.

Authors’ contributions

DSE and HPS designed the study. DSE, DM and DA acquired the data. DSE did the statistical analysis of the data. DSE, DM, DA and SM interpreted the data. DSE, DM and DA drafted the manuscript. SM and HPS provided a critical revision of the manuscript. All authors read and approved the final manuscript.



Sacral neuromodulation is well established in the treatment of refractory, non-neurogenic lower urinary tract dysfunction, but its efficacy and safety in patients with lower urinary tract dysfunction of neurological origin is unclear. Only few case series have been reported for multiple sclerosis. We prospectively evaluated the efficacy and safety of sacral neuromodulation in patients with multiple sclerosis.


Seventeen patients (13 women, 4 men) treated with sacral neuromodulation for refractory neurogenic lower urinary tract dysfunction caused by multiple sclerosis were prospectively enrolled (2007–2011). Patients had to have stable disease and confirmed neurogenic lower urinary tract dysfunction. Voiding variables, adverse events, and subjective satisfaction were assessed.


Sixteen (94 %) patients had a positive test phase with a >70 % improvement. After implantation of the pulse generator (InterStim II), the improvement in voiding variables persisted. At 3 years, the median voided volume had improved significantly from 125 (range 0 to 350) to 265 ml (range 200 to 350) (p < 0.001), the post void residual from 170 (range 0 to 730) to 25 ml (range 0 to 300) (p = 0.01), micturition frequency from 12 (range 6 to 20) to 7 (range 4 to 12) (p = 0.003), and number of incontinence episodes from 3 (range 0 to 10) to 0 (range 0 to 1) (p = 0.006). The median subjective degree of satisfaction was 80 %. Only two patients developed lack of benefit. No major complications occurred.


Chronic sacral neuromodulation promises to be an effective and safe treatment of refractory neurogenic lower urinary tract dysfunction in selected patients with multiple sclerosis.
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2015

BMC Urology 1/2015 Zur Ausgabe

Neu im Fachgebiet Urologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Urologie und bleiben Sie gut informiert – ganz bequem per eMail.